BRAF and melanoma: Given the possibility that like in the case of the Werner syndrome helicase[21], a human DDX11-specific small-molecule inhibitor will be isolated in the near future, it will be of importance to determine whether systemic therapy with such an inhibitor, alone or in combination with an inhibitor that blocks the function of FGFR1, which together with bFGF (FGF2) is a key regulator of melanoma proliferation, will have efficacy for advanced melanomas, and in particular for melanomas that are BRAF wild-type, which are the most aggressive type of advanced melanoma.